Table 4.
Comparisons of malformation frequency between HD and other diseases/controls in the cohorts.
| Discovery cohort | Validation cohort | |||||||
|---|---|---|---|---|---|---|---|---|
| Proportion with malformations | HD | Non-HD | P | OR (CI) | HD | Non-HD | P | OR (CI) |
| 8/130 (6.15%) | 12/1600 (0.75%) | 4.8 ×10-5 | 8.68 (3.48–21.63) | 7/720 (0.97%) | 3/1989 (0.15%) | 0.0050 | 6.50 (1.83–23.17) | |
| ADNC | P | OR (CI) | ADNC | P | OR (CI) | |||
| 8/685 (1.17%) | 0.0014 | 5.55 (2.06–14.88) | 1/798 (0.12%) | 0.031 | 7.83 (1.18–88.3) | |||
| DLB/ PD | P | OR (CI) | DLB/ PD | P | OR (CI) | |||
| 1/212 (0.47%) | 0.0023 | 13.84 (2.09–154.3) | 0/ 118 (0%) | 0.60 | – | |||
| Control | P | OR (CI) | Control | P | OR (CI) | |||
| 2/235 (0.85%) | 0.0049 | 7.64 (1.84–36.03) | 1/626 (0.16%) | 0.075 | 6.14 (0.8–69.27) | |||
In contrast to the discovery cohort, where the figures represent the total number of whole brains examined, the figures in the validation cohort represent the total number of half brains. P values represent two-sided Fisher’s exact tests comparing the frequency of heterotopias in HD and that of the other respective conditions.